Table 3 Cycles characteristics with and without AKI and analysis
Variable | All (n = 110) | AKI cycles (n = 38) | No AKI cycles (n = 71) | p |
|---|---|---|---|---|
Wheight loss > 10%, n | 51 (46%) | 19 (50%) | 31 (44%) | 0.67 |
BMI < 18,5, n | 21 (19%) | 5 (13%) | 16 (23%) | 0.31 |
Hypoprotidemia, n | 32 (30%) | 14 (38%) | 17 (25%) | 0.25 |
Dose reduction cisplatin, n | 21 (19%) | 3 (8%) | 18 (25%) | 0.039 |
Dose reduction cetuximab, n | 14 (13%) | 4 (11%) | 10 (14%) | 0.77 |
Cisplatin anteriority, n | 16 (15%) | 9 (24%) | 7 (10%) | 0.086 |
Hypokaliemia, n | 11 (10%) | 4 (11%) | 7 (10%) | 1 |
\({U}_{sen}\)>8, n | 78 (70.9%) | 21 (55%) | 56 (79%) | 0.018 |
Initital creatininemia, mean (± standard deviation) | 62.4 (15.0) | 62.5 (13.9) | 62.0 (17.3) | 0.87 |
D1 + D2 diurese, mean (± standard deviation) | 5.8 (2.4) | 5.5 (2.4) | 5.9 (2.5) | 0.41 |
Hydration D1 + D2, mean (± standard deviation) | 4.8 (1.2) | 4.6 (1.1) | 4.9 (1.2) | 0.28 |
History of alcohol (> 4U/day) and tobacco abuse (≥ 10 pack-years), n | 57 (52%) | 23 (61%) | 33 (46%) | 0.23 |
cardiovascular impairment, n | 52 (47%) | 21 (55%) | 31 (44%) | 0.34 |
hepatic impairment, n | 10 (9%) | 4 (11%) | 6 (8.5%) | 0.74 |
Metastasis, yes, n | 57 (52%) | 16 (42%) | 40 (56%) | 0.22 |
Enteral nutrition, n | 32 (29%) | 13 (34%) | 19 (27%) | 0.55 |
Concomitant treatments | ||||
Diuretics, n | 2 (2%) | 1 (2.6%) | 1 (1.4%) | 1 |
Cardiac treatments, n | 24 (22%) | 13 (34%) | 11 (16%) | 0.03 |
PPIs, n | 74 (67%) | 25 (66%) | 48 (68%) | 1 |
Metoclopramide, n | 30 (27%) | 11 (29%) | 19 (27%) | 0.99 |
Ondansetron, n | 89 (81%) | 31 (82%) | 58 (82%) | 1 |
Morphine and derivates, n | 41 (37%) | 17 (45%) | 24 (34%) | 0.36 |
Potentially nephrotoxic antibiotics, n | 8 (7%) | 3 (7.9%) | 5 (7%) | 1 |
NSAIDs, n | 0 (0%) | 0 (%) | 0 (%) | 1 |
Number of nephrotoxic or interacting co-medications ≥ 3 | 40 (37%) | 18 (47.4%) | 22 (31.0%) | 0.14 |